A DESCRIPTION OF NAUSEA AND VOMITING DURING THE PERI-HEMATOPOETIC TRANSPLANT PERIOD USING A RESEARCH ASSESSMENT TOOL MODIFIED FOR CLINICAL USE.

2.50
Hdl Handle:
http://hdl.handle.net/10755/165223
Category:
Abstract
Type:
Presentation
Title:
A DESCRIPTION OF NAUSEA AND VOMITING DURING THE PERI-HEMATOPOETIC TRANSPLANT PERIOD USING A RESEARCH ASSESSMENT TOOL MODIFIED FOR CLINICAL USE.
Author(s):
Douglas, Tracy
Author Details:
Tracy Douglas, MSN RN OCN, Clinical Nurse Specialist of Bone Marrow Transplan, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA, email: Dougltr@jhmi.edu
Abstract:
Patients undergoing hematopoetic stem cell transplant (HSCT) have acute and delayed chemotherapy induced nausea and vomiting; nausea and vomiting related to other medications, graft versus host disease, and infections throughout the peri-HSCT period. Healthcare providers underestimate nausea and vomiting and even low amounts are associated with a decreased quality of life in patients with cancer. The amount of emesis can be documented however that does not account for nausea and distress from these symptoms. Over the last five years nausea and vomiting at our comprehensive cancer center has been accessed using a research tool called, "The Index of Nausea and Vomiting, and Retching" (INV-2) scale developed in 1999 by Verna Rhodes. The category of retching was removed from the tool, leaving a 16 point maximum scale; accessing nausea, vomiting, and a patient's distress to both of theses symptoms on a zero to four, scale. We have used this scale clinically to determine the need for a change in clinical management if the patient has a score of four or greater. The purpose of this project is to analyze quantifiable and objective nursing assessment data from a modified INV-2 scale. The modified INV-2 score data was mined for daily scores from 13 patients undergoing allogeneic HSCT. Nurses had better than 80% compliance using this tool CINV is controlled, with 0 percent of patients with an INV-2 > 4. However, from the day of transplant to day 22, 30%- 70% of patients had an INV-2 score > 4. The data show that nausea and vomiting related to the delayed effects of chemotherapy, other medications, infections and unknown factors remain a large problem in the peri-HSCT period. One obstacle to conducting performance improvement or research in a clinical area is obtainment of consistent and quantifiable data. The modified INV-2 has been used for five years with good compliance. Our experiences with this scale will help us better understand nausea and vomiting in our population, improve clinical care and partner with medical and pharmacy colleagues for performance improvement or potentially research.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleA DESCRIPTION OF NAUSEA AND VOMITING DURING THE PERI-HEMATOPOETIC TRANSPLANT PERIOD USING A RESEARCH ASSESSMENT TOOL MODIFIED FOR CLINICAL USE.en_GB
dc.contributor.authorDouglas, Tracyen_US
dc.author.detailsTracy Douglas, MSN RN OCN, Clinical Nurse Specialist of Bone Marrow Transplan, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA, email: Dougltr@jhmi.eduen_US
dc.identifier.urihttp://hdl.handle.net/10755/165223-
dc.description.abstractPatients undergoing hematopoetic stem cell transplant (HSCT) have acute and delayed chemotherapy induced nausea and vomiting; nausea and vomiting related to other medications, graft versus host disease, and infections throughout the peri-HSCT period. Healthcare providers underestimate nausea and vomiting and even low amounts are associated with a decreased quality of life in patients with cancer. The amount of emesis can be documented however that does not account for nausea and distress from these symptoms. Over the last five years nausea and vomiting at our comprehensive cancer center has been accessed using a research tool called, "The Index of Nausea and Vomiting, and Retching" (INV-2) scale developed in 1999 by Verna Rhodes. The category of retching was removed from the tool, leaving a 16 point maximum scale; accessing nausea, vomiting, and a patient's distress to both of theses symptoms on a zero to four, scale. We have used this scale clinically to determine the need for a change in clinical management if the patient has a score of four or greater. The purpose of this project is to analyze quantifiable and objective nursing assessment data from a modified INV-2 scale. The modified INV-2 score data was mined for daily scores from 13 patients undergoing allogeneic HSCT. Nurses had better than 80% compliance using this tool CINV is controlled, with 0 percent of patients with an INV-2 > 4. However, from the day of transplant to day 22, 30%- 70% of patients had an INV-2 score > 4. The data show that nausea and vomiting related to the delayed effects of chemotherapy, other medications, infections and unknown factors remain a large problem in the peri-HSCT period. One obstacle to conducting performance improvement or research in a clinical area is obtainment of consistent and quantifiable data. The modified INV-2 has been used for five years with good compliance. Our experiences with this scale will help us better understand nausea and vomiting in our population, improve clinical care and partner with medical and pharmacy colleagues for performance improvement or potentially research.en_GB
dc.date.available2011-10-27T12:14:42Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:14:42Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.